Abstract
γδ T cells are not MHC restricted, elicit cytotoxicity against various malignancies, are present in early post-transplant phases in novel stem cell transplantation strategies and have been shown to mediate antibody-dependent cellular cytotoxicity (ADCC) with monoclonal antibodies (mAbs). These features make γδ T cells promising effector cells for antibody-based immunotherapy in pediatric patients with B-lineage acute lymphoblastic leukemia (ALL). To evaluate combination of human γδ T cells with CD19 antibodies for immunotherapy of B-lineage ALL, γδ T cells were expanded after a GMP-compliant protocol and ADCC of both primary and expanded γδ T cells with an Fc-optimized CD19 antibody (4G7SDIE) and a bi-specific antibody with the specificities CD19 and CD16 (N19-C16) was evaluated in CD107a-degranulation assays and intracellular cytokine staining. CD107a, TNFα, and IFNγ expression of primary γδ T cells were significantly increased and correlated with CD16-expression of γδ T cells. γδ T cells highly expressed CD107a after expansion and no further increased expression by 4G7SDIE and N19-C16 was measured. Cytotoxicity of purified expanded γδ T cells targeting CD19-expressing cells was assessed in both europium-TDA release and in an impedance-based label-free method (using the xCELLigence system) measuring γδ T cell lysis in real-time. Albeit in the 2 h end-point europium-TDA release assay no increased lysis was observed, in real-time xCELLigence assays both significant antibody-independent cytotoxicity and ADCC of γδ T cells were observed. The xCELLigence system outperformed the end-point europium-TDA release assay in sensitivity and allows drawing of conclusions to lysis kinetics of γδ T cells over prolonged periods of time periods. Combination of CD19 antibodies with primary as well as expanded γδ T cells exhibits a promising approach, which may enhance clinical outcome of patients with pediatric B-lineage ALL and requires clinical evaluation.
Highlights
Pediatric B-lineage acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and the leading cause of cancer-related death during childhood [1]
We evaluated the combination of primary and expanded human γδ T cells with CD19 antibodies for immunotherapy of pediatric B-lineage ALL and established an label-free method, facilitating the long-term and real-time monitoring of γδ T cell-mediated antibody-independent (AIC) and antibody-dependent cellular cytotoxicity (ADCC)
This indicates that a strong activation may be needed for γδ T cell-mediated ADCC
Summary
Pediatric B-lineage acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and the leading cause of cancer-related death during childhood [1]. In contrast to αβ T cells, γδ T cells are not restricted by MHC molecules, which makes them unlikely to elicit graft versus host disease (GvHD) based on HLA alloreactivity [5]. This feature makes γδ T cells potent effector cells during early lymphopenic post-transplant phase and in cell-based immunotherapy after SCT. Engagement of CD16 induces a potent activating signal, which overcomes inhibitory signals and results in one or more of the effector functions ADCC, cytokine response, and www.frontiersin.org γδ T cell ADCC with CD19 antibodies phagocytosis [13]. CD16 is highly expressed by natural killer (NK) cells and by other hematopoietic cells including macrophages and granulocytes
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.